Susceptibility of Chlamydia pneumoniae to azithromycin and doxycycline: Methodological aspects on the determination of minimal inhibitory and minimal bactericidal concentrations

Scandinavian Journal of Infectious Diseases

Volumn 29, Issue 5, 1997, Pages 513-516

  Nyström Rosander, Christina ^a   Hultén, Kristina ^a   Gustavsson, Ingegerd ^a   Cars, Otto ^a   Engstrand, Lars ^a   Hjelm, Eva ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; DOXYCYCLINE;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; CHLAMYDOPHILA PNEUMONIAE; COMPARATIVE STUDY; CONTROLLED STUDY; INTRACELLULAR KILLING; METHODOLOGY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; TIME;

EID: 0030712028     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.3109/00365549709011865     Document Type: Article

References (17)

1. Grayston JT, Kuo CC, Campbell LA, Wang SP. Chlamydia pneumoniae sp. nov. for Chlamydia sp. strain TWAR. Int J Systemic Bacteriol 1989; 39: 88-90.
2. Grayston, JT, Campell LA, Wang S-P. A new respiratory tract pathogen: Chlamydia pneumoniae strain, TWAR. J Infect Dis 1990; 161: 618-25.
3. Kuo CC, Jackson LA, Campbell LA, Grayston JT. Chlamydia pneumoniae (TWAR). Clin Microbiol Rev 1995; 8: 451-61.
4. Hammerschlag MR, Chirgwin K, Roblin PM, Gelling M, Dumornay W, Mandel L, Smith P, Schachler J. Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis 1992; 14: 178-82.
5. Malinverni R, Kuo C-C, Campell LA, Lee A, Grayston JT. Effects of two antibiotic regimens on course and persistence of experimental Chlamydia pneumoniae Twar pneumonitis. Antimicrob Agents Chemother 1995; 39: 45-9.
6. Chirgwin K, Roblin PM, Hammerschlag MR. In vitro susceptibilities of Chlamydia pneumoniae (Chlamydia sp. strain TWAR). Antimicrob Agents Chemother 1989; 33: 1634-5.
7. Cooper MA, Baldwin D, Matthews RS, Andrews JM, Wise R. In-vitro susceptibility of Chlamydia pneumoniae (TWAR) to seven antibiotics. J Antimicrob Chemother 1991; 28: 407-13.
8. Hammerschlag MR, Qumei KK, Roblin PM. In vitro activities of azithromycin, clarithromycin, I-ofloxacin and other antibiotics against Chlamydia pneumoniae. Anlimicrob Agents Chemother 1992; 36: 1573-4.
9. Welsh LE, Gaydos CA, Quinn TC. In vitro evaluation of activities of azithromycin, erythromycin and tetracycline against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother 1992; 36: 291-4.
10. Agacfidan A, Moncada J, Schachter J. In vitro activity of Azithromycin (CP-62,993) against Chlamydia trachomatis and Chlamydia pneumoniae. Antimicrob Agents Chemother 1993; 37: 1746-8.
11. Hammerschlag MR, Hyman CL, Roblin M. In vitro activities of five quinolones against Chlamydia pneumoniae. Antimicrob Agents Chemother 1992; 36: 682-3.
12. Fenelon LE, Mumatz G, Ridgway GL. The in-vitro susceptibility of Chlamydia pneumoniae. J Antimicrob Chemother 1990; 26: 763-7.
13. Hultén K, Cars O, Hjelm E, Engstrand L. In-vitro activity of azithromycin against intracellular Helicobacter pylori. J Antimicrob Chemother 1996; 37: 483-9.
14. Gladue RP, Bright GM, Isaacson RE, Newborg MF. In vitro and in vivo uptake of azithromycin (CP-62.993) by phagocytic cells; possible mechanism of delivery and release at sites of infection. Antimicrob Agents Chemother 1989; 33: 277 82.
15. Panteix G, Guillaumond B, Harf R, Desbos A, Sapin V, Leclercq M, Perrin-Fayolle M. In-vitro concentration of azithromycin in human phagocytic cells. J Antimicrob Chemother 1993; 31: (Suppl E) 1-4.
16. Wyrick PB, Davis CD, Knight ST, Choong J. In-vitro activity of azithromycin on Chlamydia trachomatis infected polarized human endometrial epithelial cells. J Antimicrob Chemother 1993; 31: 139-50.
17. Gnarpe J, Eriksson K, Gnarpe H. In vitro activities of azithromycin and doxycycline against 15 islolates of Chlamydia pneumoniae. Antimicrob Agents Chemother 1996; 40: 1843-5.